Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting approximately 10.55 million adults in the United States and 37.6 million people worldwide. AF is associated with significantly increased risks of stroke, heart failure, myocardial infarction, dementia, chronic kidney disease, and mortality.
The prevalence of AF increases substantially with age, with a lifetime risk of approximately 1 in 3 for individuals over 40 years. Recent data shows an overall prevalence of 3.89% among U.S. adults, with notable geographic and demographic variations—higher rates in the Midwest, South, and Northeast regions, among older adults, males, non-Hispanic White individuals, and those with lower socioeconomic status.
Key modifiable risk factors include obesity, hypertension, diabetes, obstructive sleep apnea, excessive alcohol consumption, smoking, and physical inactivity.
AF increases stroke risk approximately fivefold (about 5% per year), though this varies based on individual risk factors.
The condition is also associated with increased all-cause mortality and cardiovascular complications.
The management of atrial fibrillation has three pillars to it.
1. Stroke prevention.
2. Rate control.
3. Rhythm control.
Anticoagulation is the cornerstone of stroke prevention for patients with an estimated stroke risk of 2% or greater per year.
The CHA₂DS₂-VASc score guides anticoagulation decisions, with a score of ≥2 indicating need for therapy.
Direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and edoxaban are preferred over warfarin due to lower bleeding risks. Aspirin is not recommended for stroke prevention due to inferior efficacy.
Rate control is typically achieved with beta-blockers, calcium channel blockers, or digoxin.
Rhythm control with antiarrhythmic drugs (such as amiodarone, flecainide, or sotalol) may be considered for symptomatic patients, particularly those with recent-onset AF or heart failure with reduced ejection fraction.
The 2023 American College of Cardiology /American Heart Association/Heart Rhythm Society/American College of Physicians Guideline emphasizes a comprehensive approach incorporating stroke prevention, symptom management, and cardiovascular risk factor optimization at all stages.
Catheter ablation, primarily pulmonary vein isolation, is increasingly recognized as first-line therapy for symptomatic paroxysmal AF, offering superior symptom relief and reduced progression to persistent AF compared to antiarrhythmic drugs.
Ablation is particularly recommended for patients with heart failure and reduced ejection fraction, as it improves quality of life, left ventricular function, and cardiovascular outcomes including mortality and heart failure hospitalization rates.
Electrical cardioversion may be appropriate for acute rhythm control, though anticoagulation before and after cardioversion is warranted when AF has been present for ≥48 hours or for unknown duration.
Lifestyle and risk factor modification—including weight loss, exercise, smoking cessation, alcohol reduction, and blood pressure control—are recommended across all stages to prevent AF onset, reduce recurrence, and minimize complications.
Aditya Mehra, MD, FACC, FSCAI
For additional information on heart related topic, check out Dr Mehra’s podcast:
cardiovascular therapeutics unplugged on Spotify and Apple
And on Instagram @all_things_cardiac.
